To faciliate the change process, companies must educate MSLs and reps to stay out of the grant-submission process. The new roles and job description should reflect this new regulatory landscape.
Product managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva